Corcept Therapeutics (CORT) Misses Q2 EPS by 4c; Lowers Outlook, $100M Stock Buyback
Tweet Send to a Friend
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.20, $0.04 worse than the analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
